CHICAGO (EGMN) - Tasquinimod, an experimental antiangiogenic agent, doubled median progression-free survival of chemotherapy-naive patients with metastatic, castration-resistant prostate cancer in a placebo-controlled, phase II randomized trial."This is the first controlled trial to demonstrate an improvement in median progression free survival" using PCWG2 (Prostate Cancer Clinical Trial Working Group)-defined radiologic criteria, said principal investigator Dr. Roberto Pili, professor of oncology...